Name: Doxycycline HCl
Brand: Selleck Chemicals
SKU: S4005
Availability: InStock
Rating: 5 (2 reviews)

Jump to

Quality Control

Batch: Purity: 99.82%

99.82

Related Targets	HDAC Caspase Proteasome Secretase HCV Protease Cysteine Protease Tyrosinase HIV Protease DPP Serine Protease
Other MMP Inhibitors	Ilomastat (GM6001) Marimastat (BB-2516) Batimastat (BB-94) SB-3CT T-5224 Nobiletin NSC 405020 MMP-9-IN-1 Cordycepin JNJ0966

Solubility

In vitro
Batch:

DMSO : 96 mg/mL (199.62 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.800mg/ml (9.98mM)	Taking the 1 mL working solution as an example, add 50 μL of 96 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.600mg/ml (1.25mM)	Taking the 1 mL working solution as an example, add 50 μL of 12 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	480.9	Formula	C₂₂H₂₄N₂O₈.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	10592-13-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	MMP
In vitro	Doxycycline (50 μM) completely inhibits degradation of type II collagen, but not that of type I collagen in rheumatoid synovial fibroblasts and endothelial cells. Doxycycline (50 μM) down-regulated MMP-8 induction, at both the mRNA and protein levels in rheumatoid synovial fibroblasts and endothelial cells. Doxycycline not only inhibits MMP-8 and MMP-9 (gelatinase B) activity, but also the synthesis of MMPs in human endothelial cells. Doxycycline (50 μM) completely inhibits the phorbol-12-myristate-13-acetate (PMA)-mediated induction of MMP-8 and MMP-9, as measured by Western blotting and gelatin zymography, respectively. Doxycycline inhibits the LPS-induced IL-1beta increase in the mRNA and protein amounts in the corneal epithelium and upregulates the expression of the anti-inflammatory IL-1 RA protein in human cultured corneal epithelium. Doxycycline reduces the steady state level of the cellular ICE protein but does not affect the level of ICE transcripts. Doxycycline significantly decreases IL-1beta bioactivity in the supernatants from LPS-treated corneal epithelial cultures.
In vivo	Doxycycline (25 mg/day) prevents the structural deterioration of aortic elastin without decreasing the influx of inflammatory cells in Wistar rats. Doxycycline (25 mg/day) markedly suppresses increased aortic wall production of 92 kD gelatinase in Wistar rats. Doxycycline reduces the activity of matrix metalloproteinase (MMP)-2 and MMP-9 in the arterial wall, and inhibits smooth muscle cell migration from media to intima by 77% at 4 days after balloon injury in rats. Doxycycline reduces the replication of smooth muscle cells in the intima in rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/9395486/ [2] https://pubmed.ncbi.nlm.nih.gov/9972133/ [3] https://pubmed.ncbi.nlm.nih.gov/10937565/ [4] https://pubmed.ncbi.nlm.nih.gov/11891205/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-20)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07485010	NOT_YET_RECRUITING	Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease	The University of Queensland	2027-04	PHASE2
NCT07704957	NOT_YET_RECRUITING	Chlamydia Females; Gonorrhea Female; Syphilis Female; Adherence; Prophylaxis; Prevention	Tulane University	2027-01-01	PHASE4
NCT07488949	RECRUITING	Chronic Endometritis	Fang Wang	2024-04-09
NCT07164131	RECRUITING	Community-acquired Pneumonia	Mayo Clinic	2025-09-15	PHASE4
NCT05473520	RECRUITING	Tuberculosis; Acute Coronary Syndrome; Pulmonary Hypertension (Diagnosis)	National University Hospital, Singapore	2023-05-24	PHASE3
NCT07658976	NOT_YET_RECRUITING	HIV Infection; Sexually Transmitted Infection	HIV Prevention Trials Network	2026-09-01	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Doxycycline HCl MMP inhibitor

Chemical Structure

Molecular Weight: 480.9